{"id":"NCT01721109","sponsor":"Gilead Sciences","briefTitle":"Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents","officialTitle":"A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-12-06","primaryCompletion":"2015-10-22","completion":"2018-01-29","firstPosted":"2012-11-05","resultsPosted":"2017-04-10","lastUpdate":"2018-08-17"},"enrollment":50,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acquired Immunodeficiency Syndrome","HIV Infections"],"interventions":[{"type":"DRUG","name":"EVG/COBI/FTC/TDF","otherNames":["StribildÂ®"]}],"arms":[{"label":"EVG/COBI/FTC/TDF","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to evaluate the steady-state pharmacokinetics (PK) and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) single-tablet regimen (STR) (Part A) and to evaluate the safety and tolerability of EVG/COBI/FTC/TDF STR through Week 48 (Part B) in HIV-1 infected, antiretroviral (ARV) treatment-naive adolescents.\n\nA total of 50 adolescent participants (12 to \\< 18 years of age) will be enrolled to receive EVG/COBI/FTC/TDF as follows:\n\n* Part A: Twelve to 16 eligible participants will be enrolled to evaluate steady-state PK, and confirm the dose, with the intent to enroll at least 4 participants 12 to \\< 15 and at least 4 participants 15 to \\< 18 years of age.\n* Part B: Following confirmation of EVG exposure in at least 12 participants from Part A, 34 to 38 participants in addition to those enrolled in Part A will be enrolled to evaluate the safety, tolerability, and antiviral activity of EVG/COBI/FTC/TDF STR.","primaryOutcome":{"measure":"For Part A, Pharmacokinetic (PK) Parameter: AUCtau of EVG","timeFrame":"Predose, 2, 4, 4.5, 5, 8, and 12 hours postdose on Day 10","effectByArm":[{"arm":"EVG/COBI/FTC/TDF","deltaMin":31620.9,"sd":13978.07}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":20,"exclusionCount":15},"locations":{"siteCount":18,"countries":["United States","South Africa","Thailand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":50},"commonTop":["Upper respiratory tract infection","Headache","Vomiting","Vitamin D deficiency","Diarrhoea"]}}